Diabetes prevention spurs development programs

Researchers at a group of big drug companies, including GSK, Takeda and Novartis, have begun to study whether drugs currently prescribed to treat diabetes can be used to prevent the disease. The winners in this field can potentially open up a huge new market for drugs that already offer a good safety profile. Amylin and Eli Lilly are both active here as well. Some analysts peg the market for diabetes-prevention at $15 billion. Some 54 million Americans are considered pre-diabetic.

- read The Wall Street Journal report on diabetes therapies (sub. req.)

Suggested Articles

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.

The role gives one of the driving forces behind Bristol Myers Squibb’s $74 billion takeover of Celgene the chance to help build biotechs.